Giuseppe Caruso, Gynecology Oncology Specialist at the European Institute of Oncology, shared on LinkedIn:
“How can we choose between three different ICIs in endometrial cancer?
This was one of the most compelling questions I addressed today at ‘New Insights into Endometrial Cancer Management,’ hosted at IEO Istituto Europeo di Oncologia, during my presentation on ‘MMRd advanced or relapsed disease: first-line treatment’.
Here’s a slide I presented today. With RUBY (dostarlimab), NRG-GY018 (pembrolizumab), and DUO-E (durvalumab) all showing consistent efficacy and safety in MMRd endometrial cancer, to me, the choice comes down to where each patient best “fits” and also to practicality for both patients and hospitals:
- Infusion frequency: I think every 6 weeks (dostarlimab, pembrolizumab) is more convenient than every 4 weeks
- Subcutaneous administration (pembrolizumab) may offer a quick, easy option — and help ease day-hospital saturation
- Treatment duration: 2–3 years (dostarlimab, pembrolizumab) vs. until progression (durvalumab) — it’s reassuring to know these results were achieved with ICI stopped at 2–3 years, especially looking ahead to a possible role for reduced IO duration and subsequent IO rechallenge
- Platinum-free interval: patients with a 6–12 month PFI were included only in RUBY
- Eligibility criteria (e.g., high-risk stage IIIC1 or IIIC2, carcinosarcoma inclusion) that are broader in the RUBY trial
- Differences in costs
What’s your take – how do you choose between ICIs?
The endometrial cancer landscape keeps getting more exciting (and more complex!) – grateful for the chance to discuss it with such an incredible group of experts and friends.”
Other articles featuring Giuseppe Caruso on OncoDaily.